Back إنسولين NPH Arabic Insulina NPH Spanish انسولین انپیاچ Persian NPH-insuliini Finnish Insuline NPH French NPH ինսուլին Armenian 中間型インスリン Japanese NPH 인슐린 Korean NPH-insuline Dutch ଏନପିଏଚ ଇନସୁଲିନ OR
 | This article needs additional citations for verification. (November 2020) |
 A vial of NPH insulin with insulin syringe | |
| Clinical data | |
|---|---|
| Trade names | Novolin N, Humulin N, Insulatard, others |
| Other names | Neutral protamine Hagedorn insulin,[1] protamine zinc insulin (slightly different),[2] isophane insulin,[2] compound insulin zinc suspension (slightly different),[2] intermediate-acting insulin |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682611 |
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Onset of action | 90 minutes[3] |
| Duration of action | 24 hours[3] |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
Neutral Protamine Hagedorn (NPH) insulin, also known as isophane insulin, is an intermediate-acting insulin given to help control blood sugar levels in people with diabetes.[3] It is used by injection under the skin once to twice a day.[1] Onset of effects is typically in 90 minutes and they last for 24 hours.[3] Versions are available that come premixed with a short-acting insulin, such as regular insulin.[2]
The common side effect is low blood sugar.[3] Other side effects may include pain or skin changes at the sites of injection, low blood potassium, and allergic reactions.[3] Use during pregnancy is relatively safe for the fetus.[3] NPH insulin is made by mixing regular insulin and protamine in exact proportions with zinc and phenol such that a neutral-pH is maintained and crystals form.[1] There are human and pig insulin based versions.[1]
Protamine insulin was first created in 1936 and NPH insulin in 1946.[1] It is on the World Health Organization's List of Essential Medicines.[4] NPH is an abbreviation for "neutral protamine Hagedorn".[1] In 2020, insulin isophane was the 221st most commonly prescribed medication in the United States, with more than 2 million prescriptions.[5][6] In 2020, the combination of human insulin with insulin isophane was the 246th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]
- ^ a b c d e f Owens DR (1986). Human Insulin: Clinical Pharmacological Studies in Normal Man. Springer Science & Business Media. pp. 134–136. ISBN 9789400941618. Archived from the original on 2017-01-18.
- ^ a b c d British national formulary: BNF 69 (69 ed.). British Medical Association. 2015. pp. 464–472. ISBN 9780857111562.
- ^ a b c d e f g "Insulin Human". The American Society of Health-System Pharmacists. Archived from the original on 22 October 2016. Retrieved 8 January 2017.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
- ^ "InsulinIsophane - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
- ^ "Insulin Human; Insulin Isophane Human - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.